Kambiz Varmira

Kambiz Varmira

Auto-generated profile, based on publicly available information

Kambiz Varmira

Research Center of Oils and Fats, Kermanshah University of Medical Sciences, Kermanshah, Iran

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2018 in Applied Organometallic Chemistry
Verified
Journal Article
Closed access
PDF file
MHMona Hamelian
Mona Hamelian
MZMohammad Mahdi Zangeneh
Mohammad Mahdi Zangeneh
AAAbbas Amisama
Abbas Amisama
KVKambiz Varmira
Kambiz Varmira
HVHojat Veisi
Hojat Veisi

1 July 2018 in Journal of Photochemistry and Photobiology B: Biology
Verified
Journal Article
Closed access
MHMona Hamelian
Mona Hamelian
KVKambiz Varmira
Kambiz Varmira
HVHojat Veisi
Hojat Veisi

1 December 2018 in Journal of the Taiwan Institute of Chemical Engineers
Verified
Journal Article
Closed access
MHMona Hamelian
Mona Hamelian
SHSaba Hemmati
Saba Hemmati
KVKambiz Varmira
Kambiz Varmira
HVHojat Veisi
Hojat Veisi

1 June 2018 in Talanta
Verified
Journal Article
Closed access
KVKambiz Varmira
Kambiz Varmira
GMGhobad Mohammadi
Ghobad Mohammadi
MMMajid Mahmoudi
Majid Mahmoudi
RKReza Khodarahmi
Reza Khodarahmi
KRKhodabakhsh Rashidi
Khodabakhsh Rashidi
AJAli R. Jalalvand
Ali R. Jalalvand

27 September 2022 in Catalysis Letters
Verified
Journal Article
Closed access
PDF file
MHMona Hamelian
Mona Hamelian
KVKambiz Varmira
Kambiz Varmira
BKBikash Karmakar
Bikash Karmakar
HVHojat Veisi
Hojat Veisi

7 October 2013 in Journal of Drug Targeting
Verified
Journal Article
Closed access
PDF file
KVKambiz Varmira
Kambiz Varmira
SHSeyed Jalal Hosseinimehr
Seyed Jalal Hosseinimehr
ZNZohreh Noaparast
Zohreh Noaparast
SASeyed Mohammad Abedi
Seyed Mohammad Abedi
Human epidermal growth factor receptor 2 (HER2) expression has been shown to be increased in several types of human tumours. In this study, for the imaging of HER2-related tumours, a modified RNA aptamer with HER2-specific targeting was labelled with 99mTc, by using hydrazino nicotinamide (HYNIC) as the chelator in the presence of tricine or ethylenediamine-N,N′-diacetic acid (EDDA) as the co-ligand. Stability testing of the radiolabelled aptamers in the serum was performed through SDS-PAGE. The aptamer–radionuclide conjugate was evaluated for its cellular HER2-specific binding in ovarian cancer cells (SKOV-3), and its biodistribution properties were assessed in normal and SKOV-3 tumour-bearing mice. In the presence of either tricine or EDDA, the HYNIC-RNA aptamers were labelled with 99mTc at a high yield and radiochemical purity. Cellular experiments confirmed the specific binding of the RNA aptamer to the HER2 receptor. In the animal biodistribution study, uptake of the EDDA-co-liganded 99mTc-HYNIC-RNA aptamer by the liver and spleen was remarkably lower than that of the aptamer with tricine. Tumours also showed a higher accumulation of radioactivity with the EDDA-co-liganded aptamer complex. This study demonstrated EDDA to be better than tricine for use as a co-ligand with the RNA aptamer, which can be a potential tool for the molecular imaging of HER2-overexpressing cancers.